Details:
EB06 is a monoclonal antibody which targets autoreactive T cells that destroy the pigment-producing cells of the epidermis. It binds and inhibits CXCL10 as it is involved in initiation of the disease and the maintenance of vitiligo lesions.
Lead Product(s): EB06
Therapeutic Area: Immunology Product Name: EB06
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
QBKPN SSI is designed to reprogram the functional competence of immune cells to fix the immune dysregulation that typically develops with aging, providing broad immune protection, not only against COVID-19.
Lead Product(s): QBKPN SSI
Therapeutic Area: Immunology Product Name: QBKPN SSI
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: National Research Council of Canada Industrial Research Assistance Program
Deal Size: $6.6 million Upfront Cash: Undisclosed
Deal Type: Funding October 17, 2022
Details:
Persavita's experimental product is composed of three natural ingredients with known immune modulating properties. The company is gearing up to test this experimental product in Covid-19 patients through a phase 2 clinical study already authorized by Health Canada.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020